10x Genomics (NASDAQ:TXG) Earns Sell (E+) Rating from Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG - Free Report) in a research report report published on Saturday morning,Weiss Ratings reports.

TXG has been the subject of several other reports. The Goldman Sachs Group cut their target price on shares of 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a research note on Wednesday, October 30th. Barclays lowered their target price on shares of 10x Genomics from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, October 30th. Stephens reiterated an "overweight" rating and issued a $30.00 price objective on shares of 10x Genomics in a research note on Thursday, October 10th. Finally, Citigroup cut their target price on 10x Genomics from $35.00 to $23.00 and set a "buy" rating for the company in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $23.86.

10x Genomics Price Performance

Shares of NASDAQ TXG traded down $0.40 during trading hours on Friday, hitting $14.25. 2,556,858 shares of the stock were exchanged, compared to its average volume of 2,029,950. 10x Genomics has a one year low of $12.95 and a one year high of $51.22. The company's 50 day moving average is $15.06 and its 200 day moving average is $17.64. The firm has a market capitalization of $1.72 billion, a P/E ratio of -9.31 and a beta of 1.85.

Institutional Trading of 10x Genomics

A number of hedge funds and other institutional investors have recently modified their holdings of TXG. GAMMA Investing LLC boosted its position in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock valued at $35,000 after buying an additional 1,265 shares during the last quarter. Capital Performance Advisors LLP bought a new position in 10x Genomics in the third quarter valued at about $35,000. Blue Trust Inc. increased its position in 10x Genomics by 136.5% in the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after purchasing an additional 1,025 shares during the period. Sound Income Strategies LLC bought a new stake in 10x Genomics during the 3rd quarter worth about $46,000. Finally, Venturi Wealth Management LLC lifted its position in 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock valued at $55,000 after purchasing an additional 2,240 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.